je.st
news
Market Extra: Why share volume of tiny biotech Celator is surpassing that of Apple
2016-03-15 21:31:47| Biotech - Topix.net
Investors on Tuesday are more interested in what may be the newest way in more than 40 years to better treat a type of deadly blood cancer than they are the next iteration of Apple Inc.'s iPhone. shot into the stratosphere late Monday after the company reported a late-stage, Phase 3 study showed its drug Vyxeos significantly improved the average survival of patients with acute myeloid leukemia , compared with the current standard-of-care chemotherapy.
Tags: of
share
market
volume
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||